FDA Accepts NeurogesX's (NGSX) Qutenza sNDA for Review
Tweet
Share
E-mailGet Alerts NGSX Hot Sheet
Join SI Premium – FREE
NeurogesX, Inc. (Nasdaq: NGSX), reports the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental new drug application (sNDA) for Qutenza (capsaicin) 8% for the management of neuropathic pain associated with HIV-associated peripheral neuropathy (HIV-PN).
The FDA has granted Qutenza a priority six month review classification, assigning a Prescription Drug User Fee Act (PDUFA) action date of March 7, 2012.
The FDA has granted Qutenza a priority six month review classification, assigning a Prescription Drug User Fee Act (PDUFA) action date of March 7, 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FingerMotion CEO outlines AI computing expansion in North America
- Stable Sea adds two WisdomTree tokenized funds to its platform
- Pete Hegseth visits Oshkosh Corporation on Arsenal of Freedom tour
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
